Increased sophistication of immunotoxins

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 942-944

  Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CYTOKINE; DIPHTHERIA TOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN;

ANTIGEN EXPRESSION; BINDING AFFINITY; BODY WEIGHT DISORDER; CANCER REGRESSION; DRUG BINDING SITE; DYSPNEA; EDEMA; EDITORIAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMORAL IMMUNITY; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOGENICITY; KIDNEY INJURY; LIVER INJURY; LIVER TOXICITY; ONCOGENE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL ADHESION MOLECULES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; LECTINS; LEUKEMIA; MUTATION; PROTEIN BIOSYNTHESIS; PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036554955     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (30)

1. Salvatore, G., Beers, R., Kreitman, R. J., and Pastan, I. Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res., 8: 942-944, 2002.
2. Frankel, A. E., Tagge, E. P., and Willingham, M. C. Clinical trials of targeted toxins. Semin. Cancer Biol., 6: 307-317, 1995.
3. Schindler, J., Sausville, E. A., Messmann, R., Uhr, J. W., and Vitetta, E. S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin. Cancer Res., 7: 255-258, 2001.
4. Frankel, A. E., Kreitman, R. J., and Sausville, E. A. Targeted toxins. Clin. Cancer Res., 6: 326-334, 2000.
5. vanderSpek, J. C., and Murphy, J. R. Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells. Methods Enzymol., 327: 239-249, 2000.
6. Thompson, J., Stavrou, S., Weetall, M., Hexham, J. M., Digan, M. E., Wang, Z., Woo, J. H., Yu, Y., Mathias, A., Liu, Y. Y., Ma, S., Gordienko, I., Lake, P., and Neville, D. M. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng., in press.
7. Arora, N., Masood, R., Zheng, T., Cai, J., Smith, D. L., and Gill, P. S. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res., 59: 183-188, 1999.
8. Vallera, D. A., Li, C., Jin, N., Panoskaltsis-Mortari, A., and Hall, W. A. Targeting overexpressed urokinase-type plasminogen activator receptor (uPAR) on human glioblastoma with the diphtheria toxin fusion protein DTAT in nude mice. J. Natl. Cancer Inst. (Bethesda), in press.
9. Liu, S., Bugge, T. H., and Leppla, S. H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem., 276: 17976-17984, 2001.
10. Liu, S., Netzel-Arnett, S., Birkedeal-Hansen, H., and Leppla, S. H. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res., 60: 6061-6067, 2000.
11. Milne, J. C., Blanke, S. R., Hanna, P. C., and Collier, R. J. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol., 15: 661-666, 1995.
12. Vallera, D. A., Jin, N., Baldrica, J. M., Panoskaltsis-Mortari, A., Chen, S. Y., and Blazar, B. R. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res., 60: 976-984, 2000.
13. Chen, S. Y., Yang, A. G., Chen, J. D., Kute, T., King, C. R., Collier, J., Cong, Y., Yao, C., and Huang, X. F. Potent antitumour activity of a new class of tumour-specific killer cells. Nature (Lond.), 385: 78-80, 1997.
14. Beers, R., Chowdhury, P., Bigner, D., and Pastan, I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res., 6: 2835-2843, 2000.
15. 389IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjug. Chem., 9: 201-207, 1998.
16. Gorgun, G., and Foss, F. RXR-selective retinoid, bexarotene (targretin) upregulates IL2R expression and enhances sensitivity of B-chronic lymphocytic leukemia (CLL) cells to Denileukin Diftitox (ONTAK). Blood, 98: 150a, 2001.
17. Baluna, R., Coleman, E., Jones, C., Ghetie, V., and Vitetta, E. S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res., 258: 417-424, 2000.
18. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., and Vitetta, E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA, 96: 3957-3962, 1999.
19. Vitetta, E. S. Immunotoxins and vascular leak syndrome. Cancer J. Scient. Am., 6 (Suppl.): S218-S224, 2000.
20. Frankel, A. E., Powell, B. L., Hall, P. D., Mone, A. P., Molnar, I., and Kreitman, R. J. Phase I trial of a novel diphtheria toxin/GM-CSF fusion protein in refractory or relapsed acute myeloid leukemia (AML). Blood, 98: 722a, 2001.
21. 389EGF in patients with solid malignancies that express EGF receptors (EGFR). Proc. Am. Soc. Clin. Oncol., 14: 480, 1995.
22. Pai-Scherf, L. H., Villa, J., Pearson, D., Watson, T., Liu, E., Willingham, M. C., and Pastan, I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res., 5: 2311-2315, 1999.
23. Onda, M., Willingham, M. C., Wang, Q. C., Kreitman, R. J., Tsutsumi, Y., Nagata, S., and Pastan, I. Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J. Immunol., 165: 7150-7156, 2000.
24. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., and Pastan, I. Efficacy of the anti-CD22 immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med., 345: 241-247, 2001.
25. Schemmer, P., Golling, M., Kraus, T., Mayatepek, E., Herfarth, C., and Klar, E. Glycine reduces reperfusion injury in human liver transplantation: our first patients. Transplant. Proc., 33: 3750-3752, 2001.
26. Oldfield, E. H., Broaddus, W. C., Bruce, J., Trask, T., Laske, D. W., McDonald, J., Patel, S. J., Weingart, J. D., Wharen, R. E., and Youle, R. J. Phase II trial of convection-enhanced distribution of recombinant immunotoxin in patients with recurrent malignant gliomas. Proc. Am. Assoc. Neurol. Surg., 18: 94-95, 2000.
27. Hagihara, N., Walbridge, S., Olson, A. W., Oldfield, E. H., and Youle, R. J. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res., 60: 230-234, 2000.
28. Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman, R. J., and Pastan, I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA, 97: 8548-8553, 2000.
29. Huhn, M., Sasse, S., Tur, M. K., Matthey, B., Schinkothe, T., Rybak, S. M., Engert, A., and Barth, S. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res., in press.
30. Newton, D. L., Hansen, H. J., Mikulski, S. M., Goldenberg, D. M., and Rybak, S. M. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin's lymphoma. Blood, 97: 528-535, 2001.